NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE? скачать в хорошем качестве

NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

This episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war. 00:00 – Cold Open: Lilly vs Novo Shock Timing Dave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match. 03:20 – Novo Nordisk Price Cuts Explained Deep dive into Novo’s plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning. 07:25 – Tirzepatide vs Semaglutide Head to Head Trial Breakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially. 11:55 – Market Reaction and Strategic Implications Discussion of stock movement, competitive signaling, and how Novo’s pricing move may blunt Lilly’s trial victory. 14:25 – Novo Triple Agonist Data Drops Shift into Novo’s early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists. 16:00 – Comparing Novo’s Triple to Retatrutide Analysis of weight loss percentages versus Lilly’s retatrutide data and the caution required when comparing across trials. 18:15 – The Triple Agonist Era Broader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term. 20:00 – Clinical Trial Results vs Real World Reality Reminder that clinical trial outcomes do not automatically translate to everyday patient experience. 22:30 – Data Refresher on Allurion Ballon Approval Quick recap of the headline numbers and strategic landscape as innovation and pricing pressure accelerate simultaneously. https://www.OTPLinks.com ALLURION BALLOON INTERVIEW:    • @AllurionTechnologies  Gastric Balloon for...